510 likes | 790 Views
Diagnosis, Prognosis, and Management of aHUS. Program Goals. TMA Disorders Are Now Classified by Molecular Mechanism. Hereditary Disorders Resulting in TMA. Acquired Causes of TMA. Complex Mechanisms May Contribute to Acquired TMA. Effects of Uncontrolled or Excessive Complement Activation.
E N D
Complement-Mediated TMA (aHUS) Can Affect Multiple Organs, Tissues
No Role for Complement-Level Testing in the Diagnosis of aHUS
Recommendations of French Study Group for Defining PE/PI Failure
Potential for Significant Morbidity/Mortality Regardless of Overt Laboratory or Clinical Signs
Eculizumab Multinational Clinical Program Includes Broad aHUS Patient Population
Eculizumab Multinational, Multicenter Clinical Program of Prospective Trials in aHUS (N = 100)
Improvement in Hematologic Markers of Complement-mediated TMA Across All Studies at 26 weeks
Rapid and Sustained Improvement in Hematologic Markers of Complement-mediated TMA With or Without Identified Genetic Mutation
Early Eculizumab Therapy Associated With High Likelihood of Eliminating Dialysis
Safety Profile of Eculizumab in Prospective Trial of Adults With aHUS